Expand ANIX Menu
ANIX MENU

ANIX Latest Press Releases

-- December 15, 2025 --

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic PRNewswire 8:45 AM

-- December 11, 2025 --

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants PRNewswire 6:02 PM

-- December 10, 2025 --

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 PRNewswire 9:00 AM

-- November 17, 2025 --

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization PRNewswire 8:15 AM

-- November 12, 2025 --

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat Globe Newswire 11:00 AM
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s PRNewswire 9:00 AM

-- November 10, 2025 --

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 PRNewswire 10:30 AM

-- November 5, 2025 --

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic PRNewswire 8:55 AM

-- October 23, 2025 --

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference PRNewswire 8:47 AM

-- October 20, 2025 --

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology PRNewswire 8:25 AM

-- October 7, 2025 --

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial PRNewswire 8:31 AM

-- September 22, 2025 --

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium PRNewswire 8:05 AM

-- September 8, 2025 --

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival PRNewswire 8:00 AM

-- September 2, 2025 --

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference PRNewswire 8:54 AM

-- August 25, 2025 --

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference PRNewswire 9:13 AM

-- August 20, 2025 --

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology PRNewswire 8:37 AM

-- August 18, 2025 --

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial PRNewswire 9:00 AM

-- August 12, 2025 --

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology PRNewswire 8:05 AM

-- August 8, 2025 --

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference PRNewswire 9:15 AM

-- August 4, 2025 --

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial PRNewswire 8:45 AM

-- July 30, 2025 --

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology PRNewswire 8:15 AM

-- July 24, 2025 --

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s PRNewswire 8:00 AM
Market Data Delayed 15 Minutes